WO2002076480A1 - Extrait de cannabis sativa destine au traitement de la migraine - Google Patents
Extrait de cannabis sativa destine au traitement de la migraine Download PDFInfo
- Publication number
- WO2002076480A1 WO2002076480A1 PCT/MX2001/000019 MX0100019W WO02076480A1 WO 2002076480 A1 WO2002076480 A1 WO 2002076480A1 MX 0100019 W MX0100019 W MX 0100019W WO 02076480 A1 WO02076480 A1 WO 02076480A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- days
- migraine
- cures
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Definitions
- Panicles spikekes with flower and fruit of Canavis sativa L. are required. Panicles can be freshly cut or dried in the sun for three days.
- the collection of the panicles will be more convenient at sunrise until it reaches the zenith, this is due to the fact that in this time range there is less incidence of small insects, which would reduce the effect of the extract to cure migraine and after The time of the zenith is not conducive to gathering because the wise does not rise in large quantities as in the morning.
- the extract can be packaged in glass or plastic. This extract should be kept in dark cool places and away from flavorings such as perfumes, camphor or mint. Away from electrical appliances because they reduce healing effects to the extract.
- the mode of use of the plant extract is to mix 1 liter of the extract in 1 liter of pure cane alcohol. This mixture is what is provided to the patient, to a 10 drops dose every 48 hours for 30 days, then 5 drops are administered every 48 hours for 30 days and finally 2 drops daily for the next thirty days. This is for patients ten years and older.
- Psychiatric patients and drug addicts do not have stable results due to abandonment of treatment, but the extract is likely to cure if someone is concerned about administering the treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2001/000019 WO2002076480A1 (fr) | 2001-03-28 | 2001-03-28 | Extrait de cannabis sativa destine au traitement de la migraine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2001/000019 WO2002076480A1 (fr) | 2001-03-28 | 2001-03-28 | Extrait de cannabis sativa destine au traitement de la migraine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002076480A1 true WO2002076480A1 (fr) | 2002-10-03 |
Family
ID=19741766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2001/000019 WO2002076480A1 (fr) | 2001-03-28 | 2001-03-28 | Extrait de cannabis sativa destine au traitement de la migraine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2002076480A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2431105A (en) * | 2005-10-12 | 2007-04-18 | Gw Pharma Ltd | Cannabinoids for the treatment of pulmonary disorders |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562972A (en) * | 1976-01-12 | 1980-03-19 | Yissum Res Dev Co | Tetrahydrocannabinols |
-
2001
- 2001-03-28 WO PCT/MX2001/000019 patent/WO2002076480A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562972A (en) * | 1976-01-12 | 1980-03-19 | Yissum Res Dev Co | Tetrahydrocannabinols |
Non-Patent Citations (7)
Title |
---|
AMENTA V ET AL: "An epidemiological study on the activity of Cannabis in idiopathic headache", HEADACHE PATHOGENESIS: MONOAMINES, NEUROPEPTIDES, PURINES AND NITRIC OXIDE, vol. 7, 1997, pages 107 - 109, XP002902074 * |
EL-MALLAKH R S: "Marijuana and Migraine", HEADACHE, vol. 27, no. 8, September 1987 (1987-09-01), pages 442 - 443, XP002902071 * |
HOLLISTER L E: "Health aspects of cannabis", PHARMACOLOGICAL REVIEWS, vol. 38, no. 1, 1986, pages 1 - 20, XP002902072 * |
OGBORNE A C ET AL: "Who is using Cannabis as a medicine and why: an exploratory study", JOURNAL OF PSYCHOACTIVE DRUGS, vol. 32, no. 4, October 2000 (2000-10-01) - December 2000 (2000-12-01), pages 435 - 443, XP002902073 * |
R STEVENSON: "Cannabis: Proscribed of Prescribed", CHEMISTRY IN BRITAIN, vol. 34, no. 7, July 1998 (1998-07-01), pages 34 - 36, XP002902075 * |
RUSSO E: "Cannabis for migraine treatment: the once and future prescription? A historical and scientific review", 1998 INTERNATIONAL ASSOCIATION FOR THE STUDY OF PAIN, vol. 76, no. 1-2, May 1998 (1998-05-01), pages 3 - 8, XP002902070 * |
VOLFE Z ET AL: "Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients", INT. J. CLIN. PHARM. RES., vol. 5, no. 4, 1985, pages 243 - 246, XP002902069 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2431105A (en) * | 2005-10-12 | 2007-04-18 | Gw Pharma Ltd | Cannabinoids for the treatment of pulmonary disorders |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
US11304393B2 (en) | 2016-05-27 | 2022-04-19 | New West Genetics Inc. | Industrial hemp cannabis cultivars and seeds with stable cannabinoid profiles |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU725283B2 (en) | Bioadhesive pharmaceutical composition for the controlled release of active principles | |
US20060062835A1 (en) | Multi-disciplinary nicotine craving reduction kit with potentiating homeopathic elements | |
BR112020006841A2 (pt) | formulações de canabinoide sintéticas e à base de planta com ação prolongada e início rápido | |
EP0607201A1 (fr) | Composition comprenant de l's-oxiracetame destine a etre utilise comme agent nootrope | |
RU2003128642A (ru) | Улучшенная чрескожная терапевтическая система для лечения болезни паркинсона | |
WO2002041883A3 (fr) | Administration, au besoin, d'antidepresseurs tricycliques et d'autres antidepresseurs non inhibiteurs specifiques du recaptage de la serotonine (sri) pour traiter l'ejaculation precoce | |
ES2234451T1 (es) | Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion. | |
WO2002076480A1 (fr) | Extrait de cannabis sativa destine au traitement de la migraine | |
ES2249493T3 (es) | Preparaciones que tienen efecto contra los sintomas alergicos y su metodo de fabricacion. | |
EP1352955A3 (fr) | Lymphocytes activés provenant de donneur HLA compatible pour l'utilisation dans la prévention ou la traitement de tumeurs, de maladies infectiveuses ou autoimmunes, dans des méthods de traitement realisées par utilisation de ces lymphocytes; de formule medicinale ayant ces lymphocytes comme constituant principal; dans des méthodes de manufacuture de formule médicinale et la préparation de kit utilisé pour la préparation de formule médicinale | |
JP2007504268A5 (fr) | ||
RU99117143A (ru) | Применение дихлорбензилового спирта для получения лекарственного средства для местного лечения воспаления и лекарственное средство, содержащее дихлорбензиловый спирт | |
US20070249695A1 (en) | Preventive and/or Therapeutic Agents for Meniere's Disease | |
SHEEHY | True cholesteatoma: A report of two cases | |
CN106177089A (zh) | 一种治疗腹泻的药物贴片及其制备方法 | |
AU649302B2 (en) | Tricyclic pyridone derivative | |
US20070275096A1 (en) | Composition and methodology for the treatment of hearing impairment symptoms | |
De Miguel et al. | Ankylosing spondylitis and middle ear impairment. | |
Soni | Use of loose fitting copper bands over extremely mobile teeth while making impressions for immediate dentures | |
MD2355G2 (ro) | Metodă de pregătire preimplantare | |
US20060029648A1 (en) | Stimulant/desensitizer swabs | |
RU2098118C1 (ru) | Лекарственный сбор для лечения и профилактики урологических заболеваний | |
CN105231526A (zh) | 一种含有八角油及肉桂油的口罩 | |
CN105326959A (zh) | 一种治疗***功能障碍的药物组合物及其应用 | |
Voigt | Notes On The Temperature In A Case Of Advanced Pulmonary Tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |